Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.

Klisovic, Rebecca B

Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia. [electronic resource] - Leukemia & lymphoma Jun 2014 - 1332-6 p. digital

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural

1029-2403

10.3109/10428194.2013.838764 doi


Aged
Antimetabolites, Antineoplastic--administration & dosage
Cytarabine--administration & dosage
Female
Humans
Leukemia, Myeloid, Acute--diagnosis
Male
Middle Aged
Neoplasm Recurrence, Local
Oligodeoxyribonucleotides--administration & dosage